This randomized, open-label delayed treatment study assesses the safety and effect of MDMA-assisted therapy in treating 20 participants diagnosed with moderate-to-severe social anxiety disorder (SAD) of the generalized subtype.
This study will obtain an estimate of the effect size for two experimental sessions of MDMA-assisted therapy for treating social anxiety disorder on measures of safety, social anxiety, functional outcomes, psychiatric symptoms, and putative mechanisms of action.
The primary outcome of this study will be the Liebowitz Social Anxiety Scale (LSAS) administered by a blinded Independent Rater (IR). Other assessments, including physiological, self-report, and behavioral tasks will be used to assess other exploratory variables. An additional aim of the trial will be the development of a treatment manual for MDMA-AT for SAD for future research.
A study protocol has been published here.
Trial Details
Trial Number
Sponsors & Collaborators
MAPSMAPS stands for Multidisciplinary Association for Psychedelic Studies, it's the front runner in making psychedelics a legal way to use (and improve) in therapy.
Measures Used
Liebowitz Social Anxiety ScaleThe Liebowitz Social Anxiety Scale (LSAS) is a 24-item, self-rated scale used to assess how social anxiety plays a role in one's life across a variety of situations. The LSAS assesses both social anxiety in situations as well as avoidance of those situations.